Using AI to predict lung cancer risk; Grail is spending more than ever lobbying Congress

Researchers at Massachusetts General Hospital and MIT are testing an AI model to predict a patient's risk of lung cancer using a CT scan.‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

January 24, 2023 Check out STAT+

Sponsored By

STAT's latest report is an authoritative guide to the game-changing treatments and technologies for fighting cancer. Get the latest information about these novel therapies and their successes and failures. STAT+ subscribers receive 20% off.

STAT+ | As more never-smokers develop lung cancer, researchers test an AI model to predict patient risk Researchers at Massachusetts General Hospital and MIT are testing an AI model to predict a patient's risk of lung cancer using a CT scan. By Casey Ross STAT+ | Liquid-biopsy firm Grail is spending more than ever lobbying Congress The company's spending in Washington has been rising; during the fourth quarter of 2021, Grail spent $470,000 on lobbying. By Jonathan Wosen STAT+ | How one private biotech seized on JPM to emerge from stealth and tell its story The team behind Rezo Therapeutics spent weeks honing a pitch deck to appeal to attendees and explain what, exactly, they had been up to. By Allison DeAngelis Molly Ferguson for STAT STAT+ | Is mesothelin a key to tackling solid tumors? Some biotech companies are betting that it is Mesothelin, a protein found on cancer cells and also in healthy tissue, may be a key to tackling solid tumors, some biotechs believe. By Angus Chen STAT+ | After four years of big talk, mega startup Sana prepares to deliver some data CEO Steve Harr acknowledges setbacks but says Sana will start clinical trials of novel treatments for both cancer and diabetes this year. By Jason Mast STAT+ | In the search for therapies for solid tumors, companies are turning to a novel target: claudin-6 Several biotech and pharma companies have begun developing bispecific antibodies or CAR-T cell therapies targeting claudin-6. By Angus Chen Adobe STAT+ | Major purchasers predict expensive new therapies will keep driving drug price hikes The impact of the Inflation Reduction Act is expected to be modest in terms of implications for drug pricing and use, a new survey found. By Ed Silverman Listen: How blockbusters get made, new vaccines for RSV, and mRNA's Q score Journalist Nathan Vardi joins us to talk about his new book delving into the race to develop the lifesaving cancer drug now called Imbruvica. By Damian Garde and Meg Tirrell and Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

REPORTS NEWSLETTERS EVENTS STAT+

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •     Contact Us     •     Advertise with Us     •     View in Browser